210 related articles for article (PubMed ID: 37562195)
1. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G; Basik M; Niikura N; Tokunaga E; Brucker S; Penault-Llorca F; Hayashi N; Sohn J; Teixeira de Sousa R; Brufsky AM; O'Brien CS; Schmitt F; Higgins G; Varghese D; James GD; Moh A; Livingston A; de Giorgio-Miller V
ESMO Open; 2023 Aug; 8(4):101615. PubMed ID: 37562195
[TBL] [Abstract][Full Text] [Related]
2. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
5. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
6. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Bardia A; Viale G
Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
[TBL] [Abstract][Full Text] [Related]
7. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
8. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
9. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
10. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
[TBL] [Abstract][Full Text] [Related]
11. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
12. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
14. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
15. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract][Full Text] [Related]
16. Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression.
Rosso C; Voutsadakis IA
Clin Breast Cancer; 2022 Jun; 22(4):391-397. PubMed ID: 35337735
[TBL] [Abstract][Full Text] [Related]
17. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
18. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
19. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
20. UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA; Tan PH; Quinn C; Provenzano E; Shaaban AM; Deb R; Callagy G; Starczynski J; Lee AHS; Ellis IO; Pinder SE
J Clin Pathol; 2023 Apr; 76(4):217-227. PubMed ID: 36564170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
